Company
Company description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Quick Presentation Filters

Filter

      Loading ...

      Loading ...

      Loading ...

Filter

      Loading ...

      Loading ...

      Loading ...

Presentations (28)
Results
February 2024
15 slides
Investor Conference
January 2024
27 slides
Investor Presentation
December 2023
9 slides
Investor Presentation
November 2023
7 slides
Investor Presentation
November 2023
25 slides
Results
October 2023
14 slides
Investor Presentation
August 2023
26 slides
Results
July 2023
15 slides
Results
July 2023
16 slides
Results
June 2023
15 slides
Investor Presentation
June 2023
22 slides
Results
May 2023
13 slides
Investor Presentation
April 2023
22 slides
Investor Presentation
March 2023
22 slides
Results
March 2023
11 slides
Investor Presentation
February 2023
23 slides
Investor Conference
January 2023
22 slides
Results
December 2022
15 slides
Results
October 2022
19 slides
Results
July 2022
16 slides
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io